Emerging biomarkers of lymphangioleiomyomatosis

References

• Johnson SR, Taveira-DaSilva AM, Moss J. Lymphangioleiomyomatosis. Clin Chest Med. 2016 Sep;37(3):389–403. DOI:10.1016/j.ccm.2016.04.002. PubMed PMID: 27514586.
   PubMed Web of Science ®Google Scholar
• Henske EP, McCormack FX. Lymphangioleiomyomatosis – a wolf in sheep’s clothing. J Clin Invest. 2012 Nov 1;122(11):3807–3816. DOI:10.1172/JCI58709. PubMed PMID: 23114603; PubMed Central PMCID: PMC3484429.
   PubMed Web of Science ®Google Scholar
• Adriaensen ME, Schaefer-Prokop CM, Duyndam DA, et al. Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex. Clin Radiol. 2011 Jul;66(7):625–628. DOI:10.1016/j.crad.2011.02.009. PubMed PMID: 21459371.
   PubMed Web of Science ®Google Scholar
• Crino PB, Nathanson KL, Henske EP. The tuberous sclerosis complex. N Engl J Med. 2006 Sep 28;355(13):1345–1356. DOI:10.1056/NEJMra055323. PubMed PMID: 17005952.
   PubMed Web of Science ®Google Scholar
• Henske EP, Jozwiak S, Kingswood JC, et al. Tuberous sclerosis complex. Nat Rev Dis Primers. 2016 May 26;2:16035. DOI:10.1038/nrdp.2016.35. PubMed PMID: 27226234.
   PubMed Web of Science ®Google Scholar
• Carsillo T, Astrinidis A, Henske EP. Mutations in the tuberous sclerosis complex gene TSC2 are a cause of sporadic pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2000 May 23;97(11):6085–6090. PubMed PMID: 10823953; PubMed Central PMCID: PMCPMC18562.
   PubMed Web of Science ®Google Scholar
• Yu J, Astrinidis A, Henske EP. Chromosome 16 loss of heterozygosity in tuberous sclerosis and sporadic lymphangiomyomatosis. Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1537–1540. DOI:10.1164/ajrccm.164.8.2104095. PubMed PMID: 11704609.
   PubMed Web of Science ®Google Scholar
• Moir LM. Lymphangioleiomyomatosis: current understanding and potential treatments. Pharmacol Ther. 2016 Feb;158:114–124. DOI:10.1016/j.pharmthera.2015.12.008. PubMed PMID: 26713679.
   PubMed Web of Science ®Google Scholar
• Ben-Sahra I, Manning BD. mTORC1 signaling and the metabolic control of cell growth. Curr Opin Cell Biol. 2017 Apr;45:72–82. DOI:10.1016/j.ceb.2017.02.012. PubMed PMID: 28411448; PubMed Central PMCID: PMCPMC5545101.
   PubMed Web of Science ®Google Scholar
• Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol. 2009 May;10(5):307–318. DOI:10.1038/nrm2672. PubMed PMID: 19339977.
   PubMed Web of Science ®Google Scholar
• Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010 Jan;35(1):14–26. DOI:10.1183/09031936.00076209. PubMed PMID: 20044458.
   PubMed Web of Science ®Google Scholar
• McCormack FX, Travis WD, Colby TV, et al. Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. Am J Respir Crit Care Med. 2012 Dec 15;186(12):1210–1212. DOI:10.1164/rccm.201205-0848OE. PubMed PMID: 23250499; PubMed Central PMCID: PMC3622443.
   PubMed Web of Science ®Google Scholar
• McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011 Apr 28;364(17):1595–1606. DOI:10.1056/NEJMoa1100391. PubMed PMID: 21410393; PubMed Central PMCID: PMCPMC3118601. .
   PubMed Web of Science ®Google Scholar
• Koyama M, Johkoh T, Honda O, et al. Chronic cystic lung disease: diagnostic accuracy of high-resolution CT in 92 patients. AJR Am J Roentgenol. 2003 Mar;180(3):827–835. PubMed PMID: 12591705.
   PubMed Web of Science ®Google Scholar
• El-Chemaly S, Henske EP. Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer. Eur Respir Rev. 2014 Mar 1;23(131):30–35. DOI:10.1183/09059180.00008813. PubMed PMID: 24591659.
   PubMedGoogle Scholar
• Seyama K, Kumasaka T, Kurihara M, et al. Lymphangioleiomyomatosis: a disease involving the lymphatic system. Lymphat Res Biol. 2010 Mar;8(1):21–31. DOI:10.1089/lrb.2009.0018. PubMed PMID: 20235884.
   PubMed Web of Science ®Google Scholar
• Issaka RB, Oommen S, Gupta SK, et al. Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium. Am J Pathol. 2009 Oct;175(4):1410–1420. DOI:10.2353/ajpath.2009.080830. PubMed PMID: 19717640; PubMed Central PMCID: PMCPMC2751538.
   PubMed Web of Science ®Google Scholar
• Seyama K, Kumasaka T, Souma S, et al. Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. Lymphat Res Biol . 2006;4(3):143–152. DOI:10.1089/lrb.2006.4.143. PubMed PMID: 17034294.
   PubMedGoogle Scholar
• Young LR, Inoue Y, McCormack FX. Diagnostic potential of serum VEGF-D for lymphangioleiomyomatosis. N Engl J Med. 2008 Jan 10;358(2):199–200. DOI:10.1056/NEJMc0707517. PubMed PMID: 18184970; PubMed Central PMCID: PMCPMC3804557.
   PubMed Web of Science ®Google Scholar
• Young LR, Vandyke R, Gulleman PM, et al. Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest. 2010 Sep;138(3):674–681. DOI:10.1378/chest.10-0573. PubMed PMID: 20382711; PubMed Central PMCID: PMCPMC2940071.
   PubMed Web of Science ®Google Scholar
• McCormack FX, Gupta N, Finlay GR, et al. Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: lymphangioleiomyomatosis diagnosis and management. Am J Respir Crit Care Med. 2016 Sep 15;194(6):748–761. DOI:10.1164/rccm.201607-1384ST. PubMed PMID: 27628078.
   PubMed Web of Science ®Google Scholar
• Glasgow CG, Avila NA, Lin JP, et al. Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. Chest. 2009 May;135(5):1293–1300. DOI:10.1378/chest.08-1160. PubMed PMID: 19420197; PubMed Central PMCID: PMCPMC2818417.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Kumasaka T, Mitani K, et al. Bronchial involvement in advanced stage lymphangioleiomyomatosis: histopathologic and molecular analyses. Hum Pathol. 2016 Apr;50:34–42. DOI:10.1016/j.humpath.2015.11.002. PubMed PMID: 26997436
   PubMed Web of Science ®Google Scholar
• Julian LM, Delaney SP, Wang Y, et al. Human pluripotent stem cell-derived TSC2-haploinsufficient smooth muscle cells recapitulate features of lymphangioleiomyomatosis. Cancer Res. 2017 Oct 15;77(20):5491–5502. DOI:10.1158/0008-5472.CAN-17-0925. PubMed PMID: 28830860; PubMed Central PMCID: PMCPMC5645248.
   PubMedGoogle Scholar
• Cui Y, Osorio JC, Risquez C, et al. Transforming growth factor-beta1 downregulates vascular endothelial growth factor-D expression in human lung fibroblasts via the Jun NH2-terminal kinase signaling pathway. Mol Med. 2014 Mar 20;20:120–134. DOI:10.2119/molmed.2013.00123. PubMed PMID: 24515257; PubMed Central PMCID: PMCPMC3960396.
   PubMed Web of Science ®Google Scholar
• Cui Y, Steagall WK, Lamattina AM, et al. Aberrant SYK kinase signaling is essential for tumorigenesis induced by TSC2 inactivation. Cancer Res. 2017 Mar 15;77(6):1492–1502. DOI:10.1158/0008-5472.CAN-16-2755. PubMed PMID: 28202529; PubMed Central PMCID: PMCPMC5358967.
   PubMed Web of Science ®Google Scholar
• Dabora SL, Franz DN, Ashwal S, et al. Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease [clinical trial, phase II multicenter study research support, N.I.H., extramural research support, non-U.S. Gov’t]. PLoS One. 2011;6(9):e23379. DOI:10.1371/journal.pone.0023379. PubMed PMID: 21915260; PubMed Central PMCID: PMC3167813.
   PubMed Web of Science ®Google Scholar
• Young L, Lee HS, Inoue Y, et al. Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. Lancet Respir Med. 2013 Aug;1(6):445–452. PubMed PMID: 24159565; PubMed Central PMCID: PMCPMC3804556.
   PubMed Web of Science ®Google Scholar
• Xu KF, Zhang P, Tian X, et al. The role of vascular endothelial growth factor-D in diagnosis of lymphangioleiomyomatosis (LAM). Respir Med. 2013 Feb;107(2):263–268. DOI:10.1016/j.rmed.2012.10.006. PubMed PMID: 23127572.
   PubMed Web of Science ®Google Scholar
• Chang WY, Cane JL, Blakey JD, et al. Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis. Respir Res. 2012 Apr 18;13:34. DOI:10.1186/1465-9921-13-34. PubMed PMID: 22513045; PubMed Central PMCID: PMCPMC3431996.
   PubMed Web of Science ®Google Scholar
• Pacheco-Rodriguez G, Kumaki F, Steagall WK, et al. Chemokine-enhanced chemotaxis of lymphangioleiomyomatosis cells with mutations in the tumor suppressor TSC2 gene. J Immunol. 2009 Feb 01;182(3):1270–1277. PubMed PMID: 19155472; PubMed Central PMCID: PMCPMC2947111.
   PubMed Web of Science ®Google Scholar
• Aberle DR, Hansell DM, Brown K, et al. Lymphangiomyomatosis: CT, chest radiographic, and functional correlations. Radiology. 1990 Aug;176(2):381–387. DOI:10.1148/radiology.176.2.2367651. PubMed PMID: 2367651.
   PubMed Web of Science ®Google Scholar
• Avila NA, Chen CC, Chu SC, et al. Pulmonary lymphangioleiomyomatosis: correlation of ventilation-perfusion scintigraphy, chest radiography, and CT with pulmonary function tests. Radiology. 2000 Feb;214(2):441–446. DOI:10.1148/radiology.214.2.r00fe41441. PubMed PMID: 10671592.
   PubMed Web of Science ®Google Scholar
• Avila NA, Kelly JA, Dwyer AJ, et al. Lymphangioleiomyomatosis: correlation of qualitative and quantitative thin-section CT with pulmonary function tests and assessment of dependence on pleurodesis. Radiology. 2002 Apr;223(1):189–197. DOI:10.1148/radiol.2231010315. PubMed PMID: 11930066.
   PubMed Web of Science ®Google Scholar
• Argula RG, Kokosi M, Lo P, et al. A novel quantitative computed tomographic analysis suggests how sirolimus stabilizes progressive air trapping in lymphangioleiomyomatosis. Ann Am Thorac Soc. 2016 Mar;13(3):342–349. DOI:10.1513/AnnalsATS.201509-631OC. PubMed PMID: 26799509; PubMed Central PMCID: PMCPMC5015717.
   PubMed Web of Science ®Google Scholar
• Lo P, Brown MS, Kim H, et al. Cyst-based measurements for assessing lymphangioleiomyomatosis in computed tomography. Med Phys. 2015 May;42(5):2287–2295. DOI:10.1118/1.4916655. PubMed PMID: 25979023.
   PubMed Web of Science ®Google Scholar
• Young LR, Franz DN, Nagarkatte P, et al. Utility of [18F]2-fluoro-2-deoxyglucose-PET in sporadic and tuberous sclerosis-associated lymphangioleiomyomatosis. Chest. 2009 Sep;136(3):926–933. DOI:10.1378/chest.09-0336. PubMed PMID: 19349386; PubMed Central PMCID: PMCPMC3198490.
   PubMed Web of Science ®Google Scholar
• Pandit N, Yeung HW. F-18 FDG uptake in pulmonary lymphangioleiomyomatosis. Clin Nucl Med. 2001 Dec;26(12):1050–1051. PubMed PMID: 11711720.
   PubMed Web of Science ®Google Scholar
• Sun Y, Gu X, Zhang E, et al. Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells. Cell Death Dis. 2014 May 15;5:e1231. DOI:10.1038/cddis.2014.204. PubMed PMID: 24832603; PubMed Central PMCID: PMCPMC4047866.
   PubMed Web of Science ®Google Scholar
• Choo AY, Kim SG, van der Heiden MG, et al. Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell. 2010 May 28;38(4):487–499. DOI:10.1016/j.molcel.2010.05.007. PubMed PMID: 20513425; PubMed Central PMCID: PMCPMC2896794.
   PubMed Web of Science ®Google Scholar
• Banville N, Burgess JK, Jaffar J, et al. A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM). PLoS One. 2014;9(8):e105365. DOI:10.1371/journal.pone.0105365. PubMed PMID: 25133674; PubMed Central PMCID: PMCPMC4136818.
   PubMed Web of Science ®Google Scholar
• Prizant H, Sen A, Light A, et al. Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs. Mol Endocrinol. 2013 Sep;27(9):1403–1414. DOI:10.1210/me.2013-1059. PubMed PMID: 23820898; PubMed Central PMCID: PMCPMC3753421.
   PubMedGoogle Scholar
• Zhe X, Yang Y, Schuger L. Imbalanced plasminogen system in lymphangioleiomyomatosis: potential role of serum response factor. Am J Respir Cell Mol Biol. 2005 Jan;32(1):28–34. DOI:10.1165/rcmb.2004-0289OC. PubMed PMID: 15514113.
   PubMed Web of Science ®Google Scholar
• Evans SE, Colby TV, Ryu JH, et al. Transforming growth factor-beta 1 and extracellular matrix-associated fibronectin expression in pulmonary lymphangioleiomyomatosis. Chest. 2004 Mar;125(3):1063–1070. PubMed PMID: 15006970.
   PubMed Web of Science ®Google Scholar
• Priolo C, Ricoult SJ, Khabibullin D, et al. Tuberous sclerosis complex 2 loss increases lysophosphatidylcholine synthesis in lymphangioleiomyomatosis. Am J Respir Cell Mol Biol. 2015 Jul;53(1):33–41. DOI:10.1165/rcmb.2014-0379RC. PubMed PMID: 25780943; PubMed Central PMCID: PMCPMC4566115.
   PubMed Web of Science ®Google Scholar
• Duvel K, Yecies JL, Menon S, et al. Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell. 2010 Jul 30;39(2):171–183. DOI:10.1016/j.molcel.2010.06.022. PubMed PMID: 20670887; PubMed Central PMCID: PMC2946786.
   PubMed Web of Science ®Google Scholar
• Peterson TR, Sengupta SS, Harris TE, et al. mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway. Cell. 2011 Aug 05;146(3):408–420. DOI:10.1016/j.cell.2011.06.034. PubMed PMID: 21816276; PubMed Central PMCID: PMCPMC3336367.
   PubMed Web of Science ®Google Scholar
• Amemiya-Kudo M, Shimano H, Hasty AH, et al. Transcriptional activities of nuclear SREBP-1a, −1c, and −2 to different target promoters of lipogenic and cholesterogenic genes. J Lipid Res. 2002 Aug;43(8):1220–1235. PubMed PMID: 12177166.
   PubMed Web of Science ®Google Scholar
• Li C, Zhang E, Sun Y, et al. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis. PLoS One. 2014;9(10):e104809. DOI:10.1371/journal.pone.0104809. PubMed PMID: 25347447; PubMed Central PMCID: PMCPMC4210122.
   PubMed Web of Science ®Google Scholar
• Yu J, Astrinidis A, Howard S, et al. Estradiol and tamoxifen stimulate LAM-associated angiomyolipoma cell growth and activate both genomic and nongenomic signaling pathways. Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L694–700. DOI:10.1152/ajplung.00204.200300204.2003[pii]. PubMed PMID: 12922981; eng.
   PubMed Web of Science ®Google Scholar
• Prizant H, Hammes SR. Minireview: lymphangioleiomyomatosis (LAM): the “Other” Steroid-Sensitive Cancer. Endocrinology. 2016 Sep;157(9):3374–3383. DOI:10.1210/en.2016-1395. PubMed PMID: 27409646; PubMed Central PMCID: PMCPMC5007898.
   PubMed Web of Science ®Google Scholar
• Li C, Lee PS, Sun Y, et al. Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med. 2014 Jan 13;211(1):15–28. DOI:10.1084/jem.20131080. PubMed PMID: 24395886; PubMed Central PMCID: PMC3892971.
   PubMed Web of Science ®Google Scholar
• Yu JJ, Robb VA, Morrison TA, et al. Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells. Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2635–2640. DOI:10.1073/pnas.0810790106. PubMed PMID: 19202070; PubMed Central PMCID: PMCPMC2637277.
   PubMed Web of Science ®Google Scholar
• Yu J, Astrinidis A, Howard S, et al. Estradiol and tamoxifen stimulate lymphangiomyomatosis-associated angiomyolipoma cell growth and activate both genomic and non-genomic signaling pathways. Am J Physiol Lung Cell Mol Physiol. 2003 Aug 15. PubMed PMID: 12922981.
   Web of Science ®Google Scholar
• Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med. 2005 Oct 27;353(17):1768–1771. DOI:10.1056/NEJMp058190. PubMed PMID: 16251533.
   PubMed Web of Science ®Google Scholar
• Trindade AJ, Medvetz DA, Neuman NA, et al. MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM). PLoS One. 2013;8(3):e60014. DOI:10.1371/journal.pone.0060014. PubMed PMID: 23555865; PubMed Central PMCID: PMC3612076.
   PubMed Web of Science ®Google Scholar
• Lam HC, Liu, HJ, Baglini CV, et al. Rapamycin-induced miR-21 promotes mitochondrial homeostasis and adaptation in mTORC1 activated cells. Oncotarget. 2017 Sep 12;8(39):64714–64727. doi: 10.18632/oncotarget.19947
   Web of Science ®Google Scholar
• Trelinska J, Fendler W, Dachowska I, et al. Abnormal serum microRNA profiles in tuberous sclerosis are normalized during treatment with everolimus: possible clinical implications. Orphanet J Rare Dis. 2016 Sep 29;11(1):129. DOI:10.1186/s13023-016-0512-1. PubMed PMID: 27680012; PubMed Central PMCID: PMCPMC5041396.
   PubMedGoogle Scholar
• Ji RC. Lymphatic endothelial cells, lymphangiogenesis, and extracellular matrix. PubMed PMID: 16808670 Lymphat Res Biol. 2006;42:83–100. DOI:10.1089/lrb.2006.4.83
   PubMedGoogle Scholar
• Ko FW, Diba C, Roth M, et al. A comparison of airway and serum matrix metalloproteinase-9 activity among normal subjects, asthmatic patients, and patients with asthmatic mucus hypersecretion. Chest. 2005 Jun;127(6):1919–1927. DOI:10.1378/chest.127.6.1919. PubMed PMID: 15947303.
   PubMed Web of Science ®Google Scholar
• Mao JT, Tashkin DP, Belloni PN, et al. All-trans retinoic acid modulates the balance of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with emphysema. Chest. 2003 Nov;124(5):1724–1732. PubMed PMID: 14605041.
   PubMed Web of Science ®Google Scholar
• Shapiro SD. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr Opin Cell Biol. 1998 Oct;10(5):602–608. PubMed PMID: 9818170.
   PubMed Web of Science ®Google Scholar
• Matsui K, Takeda K, Yu ZX, et al. Role for activation of matrix metalloproteinases in the pathogenesis of pulmonary lymphangioleiomyomatosis. Arch Pathol Lab Med. 2000 Feb;124(2):267–275. DOI:10.1043/0003-9985(2000)124<0267:RFAOMM>2.0.CO;2. PubMed PMID: 10656737.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Fleming MV, Stetler-Stevenson WG, et al. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol. 1997 Sep;28(9):1071–1078. PubMed PMID: 9308732.
   PubMed Web of Science ®Google Scholar
• Odajima N, Betsuyaku T, Nasuhara Y, et al. Matrix metalloproteinases in blood from patients with LAM. Respir Med. 2009 Jan;103(1):124–129. DOI:10.1016/j.rmed.2008.07.017. PubMed PMID: 18760908.
   PubMed Web of Science ®Google Scholar
• Baldi BG, Araujo MS, Freitas CS, et al. Evaluation of the extent of pulmonary cysts and their association with functional variables and serum markers in lymphangioleiomyomatosis (LAM). Lung. 2014 Dec;192(6):967–974. DOI:10.1007/s00408-014-9641-2. PubMed PMID: 25201087.
   PubMed Web of Science ®Google Scholar
• Chilosi M, Pea M, Martignoni G, et al. Cathepsin-k expression in pulmonary lymphangioleiomyomatosis. Mod Pathol. 2009 Feb;22(2):161–166. DOI:10.1038/modpathol.2008.189. PubMed PMID: 19060845.
   PubMed Web of Science ®Google Scholar
• Dongre A, Clements D, Fisher AJ, et al. Cathepsin K in lymphangioleiomyomatosis: LAM cell-fibroblast interactions enhance protease activity by extracellular acidification. Am J Pathol. 2017 Aug;187(8):1750–1762. DOI:10.1016/j.ajpath.2017.04.014. PubMed PMID: 28623674.
   PubMed Web of Science ®Google Scholar
• Bast RC Jr., Feeney M, Lazarus H, et al. Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest. 1981 Nov;68(5):1331–1337. PubMed PMID: 7028788; PubMed Central PMCID: PMCPMC370929.
   PubMed Web of Science ®Google Scholar
• Gipson IK, Blalock T, Tisdale A, et al. MUC16 is lost from the uterodome (pinopode) surface of the receptive human endometrium: in vitro evidence that MUC16 is a barrier to trophoblast adherence. Biol Reprod. 2008 Jan;78(1):134–142. DOI:10.1095/biolreprod.106.058347. PubMed PMID: 17942799.
   PubMed Web of Science ®Google Scholar
• Glasgow CG, Pacheco-Rodriguez G, Steagall WK, et al. CA-125 in disease progression and treatment of lymphangioleiomyomatosis. Chest. 2017 May 30. DOI:10.1016/j.chest.2017.05.018. PubMed PMID: 28576630.
   PubMedGoogle Scholar
• Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003 Oct;3(10):781–790. DOI:10.1038/nri1199. PubMed PMID: 14523385.
   PubMed Web of Science ®Google Scholar
• Paschen A, Sucker A, Hill B, et al. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res. 2009 Aug 15;15(16):5208–5215. DOI:10.1158/1078-0432.CCR-09-0886. PubMed PMID: 19671853.
   PubMed Web of Science ®Google Scholar
• Chang YT, Wu CC, Shyr YM, et al. Secretome-based identification of ULBP2 as a novel serum marker for pancreatic cancer detection. PLoS One. 2011;6(5):e20029. DOI:10.1371/journal.pone.0020029. PubMed PMID: 21625447; PubMed Central PMCID: PMCPMC3098863.
   PubMed Web of Science ®Google Scholar
• Osterburg AR, Nelson RL, Yaniv BZ, et al. NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline. JCI Insight. 2016 Oct 06;1(16):e87270. DOI:10.1172/jci.insight.87270. PubMed PMID: 27734028; PubMed Central PMCID: PMCPMC5053147.
   PubMed Web of Science ®Google Scholar
• Karbowniczek M, Astrinidis A, Balsara BR, et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med. 2003 Apr 1;167(7):976–982. DOI:10.1164/rccm.200208-969OC. PubMed PMID: 12411287.
   PubMed Web of Science ®Google Scholar
• Lam HC, Nijmeh J, Henske EP. New developments in the genetics and pathogenesis of tumours in tuberous sclerosis complex. J Pathol. 2017 Jan;241(2):219–225. DOI:10.1002/path.4827. PubMed PMID: 27753446; PubMed Central PMCID: PMCPMC5167646.
   PubMed Web of Science ®Google Scholar
• Giannikou K, Malinowska IA, Pugh TJ, et al. Whole exome sequencing identifies TSC1/TSC2 biallelic loss as the primary and sufficient driver event for renal angiomyolipoma development. PLoS Genet. 2016 Aug;12(8):e1006242. DOI:10.1371/journal.pgen.1006242. PubMed PMID: 27494029; PubMed Central PMCID: PMCPMC4975391.
   PubMed Web of Science ®Google Scholar
• Cai X, Pacheco-Rodriguez G, Fan QY, et al. Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis. Am J Respir Crit Care Med. 2010 Dec 1;182(11):1410–1418. DOI:10.1164/rccm.201003-0489OC. PubMed PMID: 20639436; PubMed Central PMCID: PMCPMC3029931.
   PubMed Web of Science ®Google Scholar
• Crooks DM, Pacheco-Rodriguez G, DeCastro RM, et al. Molecular and genetic analysis of disseminated neoplastic cells in lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17462–17467. DOI:10.1073/pnas.0407971101. PubMed PMID: 15583138; PubMed Central PMCID: PMCPMC536045.
   PubMed Web of Science ®Google Scholar
• Cai X, Pacheco-Rodriguez G, Haughey M, et al. Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis. Chest. 2014 Jan;145(1):108–112. PubMed PMID: 24051985; PubMed Central PMCID: PMCPMC3883264.
   PubMed Web of Science ®Google Scholar
• Harari S, Elia D, Torre O, et al. Sirolimus therapy for patients with lymphangioleiomyomatosis leads to loss of chylous ascites and circulating LAM cells. Chest. 2016 Aug;150(2):e29–32. DOI:10.1016/j.chest.2016.02.654. PubMed PMID: 27502989.
   PubMed Web of Science ®Google Scholar